Drug Profile
Research programme: kidney disorder therapeutic biosimilar - Zydus Cadila
Alternative Names: Prod-1Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Class Antineoplastics; Ischaemic heart disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Kidney disorders; Myocardial infarction
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Cancer in India
- 28 Jan 2021 No recent reports of development identified for research development in Myocardial-infarction in India
- 28 Mar 2018 No recent reports of development identified for research development in Kidney-disorders in India